dpp 4 inhibitor glp 1 agonist GLP-1 Receptor Agonists Have better Outcomes Than DPP4 Inhibitors in T2D patients & CKD GLP 1 Receptor Agonists and
Description
This approach reflects the success seen with SGLT2 inhibitors, which have demonstrated significant cardioprotective and anti-inflammatory effects in conditions such as SLE, leading to their integration into clinical practice for autoimmune diseases (83)
The authors also suggest a second potential pathway independent of GLP-1 for some of the cardiovascular effects
[DOI] [PMC free article] [PubMed] [Google Scholar] 85.El-Boghdadly K., Dhesi J., Fabb P., et al
The biggest concern for many people is losing the progress theyve made, Adeyemo said
